One-shot cures for diseases are not great for business—more specifically, they’re bad for longterm profits—Goldman Sachs analysts noted in an April 10 report for biotech clients, first reported by CNBC.
The investment banks’ report, titled “The Genome Revolution,” asks clients the touchy question: “Is curing patients a sustainable business model?” The answer may be “no,” according to follow-up information provided.
[...] The potential to deliver “one shot cures” is one of the most attractive aspects of gene therapy, genetically engineered cell therapy, and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies... While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.
[...] Ars reached out to Goldman Sachs, which confirmed the content of the report but declined to comment.
(Score: 2) by qzm on Monday April 16 2018, @01:46AM (1 child)
Ummm. No.
THESE 'analysts' are looking at the pharma industry, which most certainly does NOT profit from increased productivity from healthy people.
It profits from maximising the amount of money it can extra from the medical/instruance industry, which itself profits from how terrified people are of the huge cost of treatements.
They are in a race to the top - just about everyone in the US medical/healthcare system profits more as the cost of treatement increases, so they all support increased costs.
The only question is, where does the balloon eventually pop.
(Score: 0) by Anonymous Coward on Monday April 16 2018, @10:14AM
The comment to which you replied would be a decent response to your comment; you haven't made a point.